Grindeks (GRD1R):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Grindeks (GRD1R) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10146
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ラトビア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Grindeks focuses on the research, development, manufacture and marketing of novel pharmaceuticals, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and cancer therapeutic categories. The company provides final dosage form pharmaceutical products ranging from solid form products, solution for injections to syrups and ointments. Grindeks also provides regulatory, analytical and final dosage form contract manufacturing services to pharmaceutical companies. Through subsidiaries and representative offices, the company markets its products in the European (EU) countries, the US, Canada, Russia and other CIS countries, Japan and Vietnam. Grindeks operates subsidiary companies in Latvia, Estonia, Russia and Slovakia and is headquartered in Riga, Latvia.

Grindeks (GRD1R) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Grindeks, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Grindeks, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Grindeks, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Grindeks, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
AB.LV Private Equity Fund Acquires Stake In Grindeks From East Capital 10
Partnerships 11
Riga Stradins University to Enter into Agreement with Grindeks 11
Acquisition 12
Grindeks Completes Acquisition of HBM Pharma from Dashdirect for USD24.7 Million 12
Grindeks – Key Competitors 13
Grindeks – Key Employees 14
Grindeks – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 17
Financial Announcements 17
Aug 30, 2018: Grindeks: Financial results for the first six months of 2018 17
Aug 30, 2018: Turnover of Grindeks reaches 71.5 million euro in the first six months of 2018; profit – 6.7 million euro 18
May 31, 2018: On “Grindeks” results in the first three months of 2018 19
May 07, 2018: Turnover of “Grindeks” reaches 132.4 million euro in 2017; profit – 10.0 million euro 20
Feb 28, 2018: Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10.3 million euro 21
Nov 27, 2017: On Grindeks results in the first nine months of 2017 22
Aug 28, 2017: Grindeks results in the first half-year of 2017 23
May 29, 2017: On “Grindeks” results in the first three months of 2017 24
Feb 28, 2017: Grindeks Announces results in 2016 25
Corporate Communications 26
Jan 09, 2018: Juris Bundulis re-elected as the Chairman of the Board; Ph.D. Juris Hmelnickis to become a Board Member of JSC Grindeks 26
Mar 01, 2017: Grindeks Announces the Board Change 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Grindeks, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Grindeks, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Grindeks, Deals By Therapy Area, 2012 to YTD 2018 8
Grindeks, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AB.LV Private Equity Fund Acquires Stake In Grindeks From East Capital 10
Riga Stradins University to Enter into Agreement with Grindeks 11
Grindeks Completes Acquisition of HBM Pharma from Dashdirect for USD24.7 Million 12
Grindeks, Key Competitors 13
Grindeks, Key Employees 14
Grindeks, Subsidiaries 15

List of Figures
Grindeks, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Grindeks, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Grindeks, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Grindeks (GRD1R):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hutchison China Meditech Ltd
    Hutchison China Meditech Ltd - Strategy, SWOT and Corporate Finance Report Summary Hutchison China Meditech Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Miromatrix Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a biotechnology company engaged in the development extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. The company offers MIRODERM a porcine liver-derived noncrosslinked acellular biologic wound matri …
  • Chembond Chemicals Ltd (530871):企業の財務・戦略的SWOT分析
    Chembond Chemicals Ltd (530871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Japan Oil, Gas and Metals National Corp:企業の戦略的SWOT分析
    Japan Oil, Gas and Metals National Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Hon Hai Precision Industry Co., Ltd.:企業の戦略・SWOT・財務情報
    Hon Hai Precision Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hon Hai Precision Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Pulmagen Therapeutics LLP:製薬・医療:M&Aディール及び事業提携情報
    Summary Pulmagen Therapeutics LLP (Pulmagen) formerly Argenta Discovery Ltd, is a development stage pharmaceutical company, which develops oral and inhaled medicines for chronic respiratory diseases. The company’s product pipeline includes oral CRTh2 antagonists, inhaled bronchodilators, inhaled per …
  • American Overseas Group Limited:企業の戦略・SWOT・財務分析
    American Overseas Group Limited - Strategy, SWOT and Corporate Finance Report Summary American Overseas Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Aduro BioTech Inc (ADRO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sti …
  • China Resources Gas Group Ltd (1193):企業の財務・戦略的SWOT分析
    China Resources Gas Group Ltd (1193) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sao Martinho SA (SMTO3):企業の財務・戦略的SWOT分析
    Sao Martinho SA (SMTO3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • EDF Luminus SA:企業の戦略的SWOT分析
    EDF Luminus SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Forbius:製薬・医療:M&Aディール及び事業提携情報
    Summary Forbius is a clinical stage pharmaceutical company that designs and develops biotherapeutics with selective anti-tumor properties for the treatment of cancer and fibrotic diseases. The company’s pipeline product portfolio includes AVID100, anti-EGFR antibody-drug conjugate for treating solid …
  • Vivendi S.A. (VIV):企業の財務・戦略的SWOT分析
    Vivendi S.A. (VIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Boralex Inc (BLX)-エネルギー分野:企業M&A・提携分析
    Summary Boralex Inc. (Boralex) is a renewable energy company that develops, constructs, and operates power plants. It produces electricity from wind, solar, hydro, natural gas, and wood residue sources; and sells that energy through long-term contracts. Boralex sources wood residues such as bark, wo …
  • The Home Depot, Inc.:企業のM&A・事業提携・投資動向
    The Home Depot, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Home Depot, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Novan Inc (NOVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Novan Inc (Novan) is a clinical-stage pharmaceutical company that develops nitric oxide therapies for the treatment of dermatological and oncovirus-mediated diseases. The company’s pipeline products are being developed for the treatment of acne vulgaris; genital warts; for onychomycosis and …
  • Trident Systems Incorporated:企業の戦略・SWOT・財務情報
    Trident Systems Incorporated - Strategy, SWOT and Corporate Finance Report Summary Trident Systems Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • International Paper Co:企業のM&A・事業提携・投資動向
    International Paper Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's International Paper Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • United Biscuits (UK) Limited:企業の戦略・SWOT・財務情報
    United Biscuits (UK) Limited - Strategy, SWOT and Corporate Finance Report Summary United Biscuits (UK) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Koc Holding AS:企業の戦略・SWOT・財務情報
    Koc Holding AS - Strategy, SWOT and Corporate Finance Report Summary Koc Holding AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆